Secondary sclerosing cholangitis (SSC) is a chronic cholestatic biliary disease, characterized by inflammation, obliterative fibrosis of the bile ducts, stricture formation and progressive ...

Compass Therapeutics has announced top-line data from its ongoing COMPANION-002 trial investigating its antibody-based ...

Treatment with tovecimig, formerly known as CTX-009, elicited responses in patients with biliary tract cancer, according to ...

Liver endothelial cells respond differentially to various insults, influencing the liver’s niche and disease outcomes. Here the authors show that in response to bile acid chenodeoxycholic acid ...

With changing lifestyles in recent years, Wei said the increasing incidence of metabolic-associated fatty liver disease has ...

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

or peptic ulcer disease), so healthcare providers use a specific set of diagnostic criteria to determine if your symptoms are ...

Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy ...

Minister of State for Defence and Member of Parliament from Ranchi, Sanjay Seth, is set to launch a special campaign on April ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...